This site is intended for healthcare professionals

Horizon Therapeutics plc initiates ADVANCE trial evaluating Krystexxa with methotrexate for people who previously developed anti-drug antibodies on Krystexxa monotherapy.

Read time: 1 mins
Last updated:28th May 2021
Published:28th May 2021
Horizon Therapeutics plc announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of Krystexxa (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with Krystexxa monotherapy.
Condition: Gout
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest